Month: November 2024

.After antibody-drug conjugate (ADC) professional Seagen was marketed to Pfizer in 2013 for a monstrous $43 billion, past CEO David Epstein said he was aiming

.Amidst the hereditary medicines arms race, Flagship Pioneering is actually revealing a brand-new provider to assist biotechs fine-tune the preciseness of their therapies.The endeavor production

.Intense Biotech Colleague Editor Gabrielle Masson presented the 2024 class of Tough 15 champions on the flooring of the Stock market on Wednesday.Masson looked on

.Allow’s study a chat along with Ayla Ellison, Tough Biotech Managing Editor and also Michelle Benz as they go over the highlights as well as

.FibroGen is significantly restructuring its organization, laying off 75% of its own U.S. team and also stopping assets in its lead candidate in reaction to

.After F2G’s first try to get a new course of antifungal to market was actually thwarted due to the FDA, the U.K.-based biotech has actually

.The FDA has carried out a predisposed hold on a phase 3 non-small tissue lung cancer dry run through BioNTech and OncoC4 after viewing differing

.The FDA has actually positioned Kezar Lifestyle Sciences’ lupus test on hold after the biotech hailed four fatalities throughout the stage 2b research.Kezar had actually

.After pushing back the decision meeting for Applied Rehabs’ metabolic condition medication govorestat, the FDA has now decided that a prepared consultatory board meeting will

.For Lykos Therapeutics and the provider’s potential MDMA-assisted treatment for trauma (POST-TRAUMATIC STRESS DISORDER), the hits merely keep coming..Earlier this month, Lykos was hit through